GUJTHEM Gujarat Themis Biosyn Q1 FY27 results (Apr–Jun 2026) and concall
Gujarat Themis Biosyn Limited reported strong Q1 FY27 results with significant revenue and profit growth, driven by robust demand and margin expansion. The company is actively pursuing a strategic transformation into an integrated fermentation-based CDMO player through organic capacity expansion and two key inorganic acquisitions. While these acquisitions promise long-term growth and diversification, their integration and regulatory approvals remain key focus areas.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 22.2%, net profit up 22.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 35 | 40 | 38 | 36 | 42 +20% | 43 +8% | 44 +16% | 44 +22% |
| EBITDA | 15 | 19 | 16 | 14 | 21 +40% | 21 +11% | 19 +19% | 21 +50% |
| Net profit | 11 | 13 | 12 | 9 | 14 +27% | 12 −8% | 11 −8% | 11 +22% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
